Literature DB >> 21922268

[Preoperative anemia in orthopedic surgery: clinical impact, diagnostics and treatment].

D Kendoff1, J Tomeczkowski, J Fritze, H Gombotz, C von Heymann.   

Abstract

In a national audit of elective orthopedic surgery conducted in the US, 30% of patients were found to have hemoglobin (Hgb) levels < 13 g/dl at preadmission testing. Preoperative anemia has been associated with increased mortality and morbidity after surgery, increased allogeneic blood transfusion therapy and increased rates of postoperative infection leading to a longer length of hospital stay. Because of the risks associated with allogeneic blood transfusions according to German law patients have to be offered the option of autologous transfusion if the risk associated with allogeneic blood transfusion is > 10%. However, one of these measures, the autologous blood donation, can exaggerate anemia and can increase the overall transfusion rates (allogeneic and autologous). As autologous procedures (autologous blood donation and cell salvage) are not always appropriate for anemic patients together with an expected shortage of blood and because preoperative anemia is associated with perioperative risks of blood transfusion, a standardized approach for the detection, evaluation and management of anemia in this setting was identified as an unmet medical need. A panel of multidisciplinary physicians was convened by the Society for Blood Management to develop a clinical care pathway for anemia management in elective surgery patients for whom blood transfusion is an option. In these guidelines elective surgery patients should have Hgb level determination at the latest 28 days before the scheduled surgical procedure. The patient target Hgb before elective surgery should be within the normal range (normal female ≥ 120 g/l, normal male ≥ 130 g/l). Laboratory testing should take place to further determine nutritional deficiencies, chronic renal insufficiency and/or chronic inflammatory diseases. Nutritional deficiencies should be treated and erythropoiesis-stimulating agent (ESA) therapy should be used for anemic patients in whom nutritional deficiencies have been ruled out and/or corrected.

Entities:  

Mesh:

Year:  2011        PMID: 21922268     DOI: 10.1007/s00132-011-1789-3

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  58 in total

1.  Demographic Changes: The Impact for Safe Blood Supply.

Authors:  Andreas Greinacher; Konstanze Fendrich; Wolfgang Hoffmann
Journal:  Transfus Med Hemother       Date:  2010-05-20       Impact factor: 3.747

2.  Demographic Changes in Germany up to 2060 - Consequences for Blood Donation.

Authors:  Manfred Ehling; Olga Pötzsch
Journal:  Transfus Med Hemother       Date:  2010-05-20       Impact factor: 3.747

3.  On the relative safety of intravenous iron formulations: new answers, new questions.

Authors:  Glenn M Chertow; Wolfgang C Winkelmayer
Journal:  Am J Hematol       Date:  2010-09       Impact factor: 10.047

4.  The health(y) cost of erythropoietin in orthopedic surgery.

Authors:  Dean A Fergusson; Paul Hébert
Journal:  Can J Anaesth       Date:  2005-04       Impact factor: 5.063

5.  [Health economic aspects of the use of blood and blood products].

Authors:  K Berger; L Frey; M Spannagl; W Schramm
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2006-01       Impact factor: 1.513

6.  Activity-based costs of blood transfusions in surgical patients at four hospitals.

Authors:  Aryeh Shander; Axel Hofmann; Sherri Ozawa; Oliver M Theusinger; Hans Gombotz; Donat R Spahn
Journal:  Transfusion       Date:  2009-12-09       Impact factor: 3.157

7.  Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty.

Authors:  Allen Deutsch; Janice Spaulding; Randall E Marcus
Journal:  J Arthroplasty       Date:  2006-08       Impact factor: 4.757

8.  The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty.

Authors:  G M Mundy; S J Birtwistle; R A Power
Journal:  J Bone Joint Surg Br       Date:  2005-02

9.  The influence of preclinical anaemia on outcome following total hip replacement.

Authors:  E Myers; P O'Grady; P O Grady; A M Dolan
Journal:  Arch Orthop Trauma Surg       Date:  2004-10-29       Impact factor: 3.067

10.  Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study.

Authors:  J A García-Erce; J Cuenca; S Haman-Alcober; A A Martínez; A Herrera; M Muñoz
Journal:  Vox Sang       Date:  2009-06-03       Impact factor: 2.144

View more
  5 in total

1.  Renal and Gastrointestinal Considerations in Joint Replacement Surgery.

Authors:  Benjamin Voss; Alexander Kurdi; Alexander Skopec; Jasmine Saleh; Mouhanad M El-Othmani; Joseph M Lane; William M Mihalko; Khaled J Saleh
Journal:  J Nat Sci       Date:  2015-02-01

2.  Improved patient blood management and cost saving in hip replacement surgery through the implementation of pre-operative Sucrosomial® iron supplementation: a quality improvement assessment study.

Authors:  Marco Scardino; Berardo Di Matteo; Federica Martorelli; Dario Tanzi; Elizaveta Kon; Tiziana D'Amato
Journal:  Int Orthop       Date:  2018-09-20       Impact factor: 3.075

Review 3.  [Various scenarios for billing and remuneration of preoperative management of iron deficiency anemia in the German healthcare system].

Authors:  F Piekarski; M Thalheimer; T Seyfried; F Kron; N Jung; P Sandow; S Isik; C Fuellenbach; S Choorapoikayil; U Marschall; M Winterhalter; F Wunderer; J Kloka; J-H Tellbach; K Zacharowski; P Meybohm
Journal:  Anaesthesist       Date:  2019-08       Impact factor: 1.041

4.  Patient blood management in orthopaedic surgery: a four-year follow-up of transfusion requirements and blood loss from 2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland.

Authors:  Oliver M Theusinger; Stephanie L Kind; Burkhardt Seifert; Lain Borgeat; Christian Gerber; Donat R Spahn
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

5.  Potential cost saving of Epoetin alfa in elective hip or knee surgery due to reduction in blood transfusions and their side effects: a discrete-event simulation model.

Authors:  Jörg Tomeczkowski; Sean Stern; Alfred Müller; Christian von Heymann
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.